E. Deliargyris

发表

Role of nuclear factor-kappa B (NF-kappa B) in inflammation, periodontitis, and atherogenesis.

T. Fischer, A. Baldwin, T. Nichols, 2001, Annals of periodontology.

Effect of valve design and anticoagulation strategy on 30‐day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial

C. Hengstenberg, P. Stella, G. Dangas, 2017, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.

Deepak L. Bhatt, P. Serruys, G. Dangas, 2019, JAMA cardiology.

Aspirin Resistance in Cardiovascular Disease: A Review of Prevalence, Mechanisms, and Clinical Significance

D. Sane, E. Deliargyris, Scott A McKee, 2002, Thrombosis and Haemostasis.

Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies

G. Dangas, R. Mehran, U. Baber, 2013, Journal of Thrombosis and Thrombolysis.

The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX

Deepak L. Bhatt, M. Price, H. White, 2019, Clinical cardiology.

Impact of pre‐existing or new‐onset atrial fibrillation on 30‐day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial

C. Hengstenberg, P. Boekstegers, G. Dangas, 2017, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials.

Deepak L. Bhatt, M. Price, H. White, 2018, International journal of cardiology.

Comparison of Bivalirudin Versus Heparin(s) During Percutaneous Coronary Interventions in Patients Receiving Prasugrel: A Propensity‐Matched Study

Sunil V. Rao, M. Valgimigli, A. Gershlick, 2014, Clinical cardiology.

Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study.

Sunil V. Rao, M. Valgimigli, A. Gershlick, 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions

Deepak L. Bhatt, M. Price, H. White, 2016, Circulation.

Bivalirudin started during emergency transport for primary PCI.

S. Pocock, K. Huber, P. Steg, 2013, The New England journal of medicine.

Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention.

Deepak L. Bhatt, M. Price, H. White, 2017, Journal of the American College of Cardiology.

Impact of acute infarct-related artery patency before percutaneous coronary intervention on 30-day outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention in the EUROMAX trial

D. Dudek, P. Steg, J. T. ten Berg, 2018, European heart journal. Acute cardiovascular care.

Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials

G. Stone, R. Mehran, P. Steg, 2017, European heart journal. Acute cardiovascular care.

Now You See It, Now You Don't... Intravascular Ultrasound Virtual Histology Derived Thin Cap Fibroatheroma:

E. Deliargyris, 2010 .

Intravascular ultrasound virtual histology derived thin cap fibroatheroma now you see it, now you don't...

E. Deliargyris, 2010, Journal of the American College of Cardiology.

Bivalirudin use in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Insights from the prospective, multi-centre EUROVISION registry

C. Nienaber, K. Huber, A. Picchi, 2014, Acute cardiac care.

Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction.

G. Dehmer, T. Theoharides, E. Deliargyris, 2001, American heart journal.

Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): an international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myocardial infarction transferred for primary percut

D. Dudek, K. Huber, P. Steg, 2013, American heart journal.

Prediction of 1‐year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient‐level pooled analysis from three randomized trials

B. Gersh, S. Pocock, G. Stone, 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Impact of Arterial Access Site on Outcomes After Primary Percutaneous Coronary Intervention: Prespecified Subgroup Analysis From the EUROMAX Trial

P. Steg, A. V. Van't Hof, C. Hamm, 2015, Circulation. Cardiovascular interventions.

Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial.

C. Hengstenberg, P. Boekstegers, G. Dangas, 2015, Journal of the American College of Cardiology.

Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).

Deepak L. Bhatt, M. Price, H. White, 2015, JACC. Cardiovascular interventions.

Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial

K. Huber, P. Steg, C. Hamm, 2014, European heart journal.

Bivalirudin Versus Heparin Plus a Glycoprotein IIb/IIIa Inhibitor in Patients With Non–ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment: Pooled Analysis from the ACUITY and ISAR-REACT 4 Trials

G. Stone, A. Kastrati, J. Mehilli, 2012, Circulation. Cardiovascular interventions.

Bleeding Events Before Coronary Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.

S. Pocock, G. Stone, A. Kirtane, 2016, Journal of the American College of Cardiology.

Frequency and prognostic significance of access site and non-access site bleeding and impact of choice of antithrombin therapy in patients undergoing primary percutaneous coronary intervention. The EUROMAX trial.

A. V. Van't Hof, J. T. ten Berg, U. Zeymer, 2016, International journal of cardiology.

Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy.

J. McMurray, S. Pocock, M. Simoons, 2013, European heart journal.

Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial

Deepak L. Bhatt, M. Price, H. White, 2018, European heart journal.

Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX).

Deepak L. Bhatt, M. Price, H. White, 2017, The American journal of cardiology.

Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention

Deepak L. Bhatt, M. Price, H. White, 2016, Circulation.

Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography).

D. Dudek, P. Steg, A. V. Van't Hof, 2015, JACC. Cardiovascular interventions.

Coronary artery disease following mediastinal irradiation.

E. Deliargyris, G. Lazopoulos, Spyridon I Dragomanovits, 2007, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI.

S. Pocock, G. Stone, A. Kirtane, 2017, Journal of the American College of Cardiology.

Cangrelor reduces the risk of ischemic complications in patients with single‐vessel and multi‐vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial

Deepak L. Bhatt, M. Price, M. Desai, 2017, American heart journal.

Acute Coronary Syndrome Angiography)

D. Dudek, P. Steg, P. Coste, 2015 .

Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial.

Deepak L. Bhatt, M. Price, H. White, 2019, International journal of cardiology.

Cerebral Embolism During Transcatheter Aortic Valve Replacement: The BRAVO-3 MRI Study.

C. Hengstenberg, G. Dangas, R. Mehran, 2016, Journal of the American College of Cardiology.

Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention

Deepak L. Bhatt, M. Price, H. White, 2017, Circulation. Cardiovascular interventions.

P2852 Superior clinical outcomes with abciximab versus eptifibatide: a contemporary, single centre, single operator, non-randomized comparison of 500 consecutive percutaneous coronary interventions

E. Deliargyris, 2003 .

Impact of anticoagulation regimen prior to revascularization in patients with non‐ST‐segment elevation acute coronary syndromes: The ACUITY trial

S. Steinhubl, G. Stone, W. Desmet, 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Unfractionated Heparin Reduces the Anti-Platelet Effects of Abciximab but not Eptifibatide During PCI

C. Thompson, D. Sane, G. Dehmer, 2006, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.

B. Gersh, S. Pocock, G. Stone, 2015, Journal of the American College of Cardiology.

Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial).

C. Hengstenberg, G. Dangas, S. Windecker, 2019, The American journal of cardiology.

Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials

Deepak L. Bhatt, M. Price, H. White, 2017, JAMA cardiology.

Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation

Deepak L. Bhatt, R. Mehran, P. Steg, 2022, Clinical Pharmacokinetics.

Trends in P2Y12 Inhibitor Use in Patients Referred for Invasive Evaluation of Coronary Artery Disease in Contemporary US Practice.

J. Prats, E. Deliargyris, S. Plent, 2016, The American journal of cardiology.

Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial

Deepak L. Bhatt, M. Price, H. White, 2016, Circulation. Cardiovascular interventions.

Antibodies to Platelet Factor 4/Heparin are Associated with Elevated Endothelial Cell Activation Markers in Patients with Acute Coronary Ischemic Syndromes

R. Califf, M. Simoons, M. Mascelli, 2004, Journal of Thrombosis and Thrombolysis.

Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment: Analysis From the CHAMPION PHOENIX Trial

Deepak L. Bhatt, M. Price, H. White, 2019, Circulation. Cardiovascular interventions.

Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial.

C. Hengstenberg, P. Stella, G. Dangas, 2019, International journal of cardiology.

Sex‐based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO‐3 randomized trial

C. Hengstenberg, G. Dangas, J. Webb, 2017, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX

Deepak L. Bhatt, M. Price, H. White, 2015, European heart journal.

Early clinical outcomes as a function of use of newer oral P2Y12 inhibitors versus clopidogrel in the EUROMAX trial

K. Huber, C. Hamm, F. Verheugt, 2017, Open Heart.

Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.

Deepak L. Bhatt, M. Price, H. White, 2016, JACC. Cardiovascular interventions.

Ef ﬁ cacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention The CHAMPION PHOENIX

Deepak L. Bhatt, M. Price, H. White, 2022 .

Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX

Deepak L. Bhatt, M. Price, H. White, 2021, Circulation. Cardiovascular interventions.

Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial.

Deepak L. Bhatt, M. Price, H. White, 2016, Journal of the American College of Cardiology.

Preprocedural white blood cell count and major adverse cardiac events late after percutaneous coronary intervention in saphenous vein grafts.

D. Sane, W. Little, R. Applegate, 2005, The American journal of cardiology.

Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO‐3 randomized trial

C. Hengstenberg, P. Boekstegers, G. Dangas, 2019, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions.

D. Sane, R. Applegate, M. Kutcher, 2004, The Journal of invasive cardiology.

Cocaine‐Associated Chest Pain

G. Stouffer, D. Lenihan, E. Deliargyris, 2002, The American journal of the medical sciences.

Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI: A Secondary Analysis of the HORIZONS-AMI Randomized Clinical Trial

G. Stone, A. Kirtane, G. Dangas, 2017, JAMA cardiology.

Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment–Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials

G. Stone, G. Dangas, R. Mehran, 2016, Circulation. Cardiovascular interventions.

PREDICTORS ASSOCIATED WITH ACUTE STENT THROMBOSIS AFTER PRIMARY PCI: THE EUROMAX TRIAL

D. Dudek, P. Coste, P. Clemmensen, 2014 .

Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial

J. J. Piek, Deepak L. Bhatt, P. Serruys, 2022, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention – Insights from the CHAMPION program

Deepak L. Bhatt, M. Price, H. White, 2021, American heart journal plus : cardiology research and practice.

Anti-Platelet Factor 4/Heparin Antibodies: An Independent Predictor of 30-Day Myocardial Infarction After Acute Coronary Ischemic Syndromes

R. Califf, M. Simoons, M. Mascelli, 2003, Circulation.

Minimizing femoral access complications in patients undergoing percutaneous coronary interventions: a proposed strategy of bony landmark guided femoral access, routine access site angiography and appropriate use of closure devices.

E. Deliargyris, G. Papaioannou, Spyridon I Dragomanovits, 2007, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

Bivalirudin infusion to reduce ventricular infarction: the open-label, randomised Bivalirudin Infusion for Ventricular InfArction Limitation (BIVAL) study.

J. Garot, R. V. van Geuns, G. Sideris, 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Bivalirudin versus heparin for peripheral vascular intervention: You get what you pay for…

E. Deliargyris, C. Kimmelstiel, 2017, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Periodontal disease in patients with acute myocardial infarction: prevalence and contribution to elevated C-reactive protein levels.

Sidney C. Smith, J. Beck, S. Offenbacher, 2004, American heart journal.

Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study

Deepak L. Bhatt, L. Been, D. Angiolillo, 2022, Journal of Thrombosis and Thrombolysis.

Relation of serum levels of mast cell tryptase of left ventricular systolic function, left ventricular volume or congestive heart failure.

G. Dehmer, T. Theoharides, E. Deliargyris, 2004, Journal of cardiac failure.

ISCHEMIC EVENTS OCCUR EARLY IN PATIENTS UNDERGOING PCI AND ARE REDUCED WITH CANGRELOR: FINDINGS FROM CHAMPION PHOENIX

Deepak L. Bhatt, M. Price, H. White, 2017 .

Cocaine and accelerated atherosclerosis: insights from intravascular ultrasound.

J. Hoyle, E. Deliargyris, M. B. Erwin, 2004, International journal of cardiology.

Differences in baseline characteristics and in-hospital outcomes in patients with or without prior stroke undergoing percutaneous coronary intervention.

D. Sane, R. Applegate, M. Kutcher, 2005, The Journal of invasive cardiology.

Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial

Deepak L. Bhatt, M. Price, H. White, 2016 .

Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)

Deepak L. Bhatt, M. Price, H. White, 2018, Circulation. Cardiovascular interventions.

ST-segment resolution with bivalirudin versus heparin and routine glycoprotein IIb/IIIa inhibitors started in the ambulance in ST-segment elevation myocardial infarction patients transported for primary percutaneous coronary intervention: The EUROMAX ST-segment resolution substudy

P. Steg, A. V. Van't Hof, C. Hamm, 2017, European heart journal. Acute cardiovascular care.

Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.

G. Stone, G. Dangas, A. Lincoff, 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO‐3 trial

Samin K. Sharma, C. Hengstenberg, G. Dangas, 2020, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study

Deepak L. Bhatt, L. Been, D. Angiolillo, 2022, Journal of Thrombosis and Thrombolysis.

Periodontal disease is associated with higher levels of C-reactive protein in non-diabetic, non-smoking acute myocardial infarction patients.

C. Stefanadis, C. Pitsavos, L. Papadimitriou, 2011, Journal of dentistry.

Bivalirudin in percutaneous coronary intervention: the EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry.

C. Nienaber, K. Huber, P. Steg, 2014, International journal of cardiology.

Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery—a systematic review

R. Storey, H. Adamson, M. Thielmann, 2022, Journal of thoracic disease.

Removal of Apixaban during Emergency Cardiac Surgery Using Hemoadsorption with a Porous Polymer Bead Sorbent

M. Kamler, J. Easo, M. Thielmann, 2022, Journal of clinical medicine.

Cardiotoxicity of cancer therapy.

K. Tolba, E. Deliargyris, 1999, Cancer investigation.

Mechanistic Considerations and Pharmacokinetic Implications on Concomitant Drug Administration During CytoSorb Therapy

T. Nolin, J. Scheier, A. Schneider, 2022, Critical care explorations.

Heparin or bivalirudin for non‐primary PCI: Beware of neat and simple answers…

E. Deliargyris, C. Kimmelstiel, 2017, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent

J. Douketis, E. Ohman, M. Mack, 2022, European heart journal. Cardiovascular pharmacotherapy.

Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).

S. Pocock, G. Stone, R. Mehran, 2014, Journal of the American College of Cardiology.

"Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings.

Deepak L. Bhatt, M. Price, H. White, 2016, Journal of the American College of Cardiology.

Comparison of the CytoSorb® 300 mL and Jafron HA380 hemoadsorption devices: an in vitro study

C. Hagl, A. Nierhaus, Y. Mehta, 2022, Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy.

European workshop in periodontal health and cardiovascular disease consensus document

F. Fernández‐Avilés, P. Boutouyrie, J. Deanfield, 2010 .

The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences

J. Ruiz-Rodríguez, R. Ferrer, Z. Molnár, 2021, Critical care research and practice.

Mast cell tryptase: a new biomarker in patients with stable coronary artery disease.

Sidney C. Smith, D. Sane, G. Dehmer, 2005, Atherosclerosis.

History repeats itself.

G. Dehmer, E. Deliargyris, 2001, Circulation.

Preoperative factors predisposing to early postoperative atrial fibrillation after isolated coronary artery bypass grafting.

S. Smith, G. Dehmer, E. Deliargyris, 2000, The American journal of cardiology.

Definitive repair of double-outlet right ventricle with subaortic ventricular septal defect and pulmonary atresia in adulthood.

E. Deliargyris, C. Roberts, S. McKee, 2003, The American journal of cardiology.

Focusing on Inflammation in the Treatment of Atherosclerosis

L. Newby, E. Deliargyris, Jason T. Call, 2004, Cardiology in review.

Role of Nuclear Factor‐Kappa B (NF‐κB) in Inflammation, Periodontitis, and Atherogenesis

T. Fischer, A. Baldwin, T. Nichols, 2001 .

Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials.

G. Stone, A. Kirtane, G. Dangas, 2016, The American journal of cardiology.

Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges.

C. O'connor, M. Gheorghiade, F. Zannad, 2013, International journal of cardiology.

Safety of Abciximab Administration During PCI of Patients with Previous Stroke

D. Sane, J. Riesmeyer, R. Applegate, 2005, Journal of Thrombosis and Thrombolysis.

One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial

P. Steg, J. T. ten Berg, E. Fabris, 2017, JAMA cardiology.

Outcomes in elderly and young patients with ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS‐AMI trials

G. Stone, R. Mehran, P. Steg, 2017, American heart journal.

Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure.

D. Tate, G. Dehmer, T. Theoharides, 2000, The American journal of cardiology.

Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX

Deepak L. Bhatt, M. Price, H. White, 2017, Circulation. Cardiovascular interventions.

Cangrelor in Older Patients Results Association Between Age and Cardiovascular Events in CHAMPION PHOENIX

Deepak L. Bhatt, M. Price, H. White, 2017 .

Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO‐3 randomized trial

C. Hengstenberg, P. Boekstegers, G. Dangas, 2019, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

The Potential Role of Extracorporeal Cytokine Removal in Hemodynamic Stabilization in Hyperinflammatory Shock

J. Scheier, H. Adamson, Z. Molnár, 2021, Biomedicines.

Urgent Coronary Artery Bypass Grafting Complicated by Systemic Inflammatory Response from Fulminant Herpes Zoster Successfully Managed with Adjunct Extracorporeal Hemoadsorption: A Case Report

M. Thielmann, A. Ruhparwar, D. Wendt, 2022, Journal of clinical medicine.

Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study

Deepak L. Bhatt, U. Marathi, D. Angiolillo, 2019, Journal of Thrombosis and Thrombolysis.

CytoSorb Therapy in COVID-19 (CTC) Patients Requiring Extracorporeal Membrane Oxygenation: A Multicenter, Retrospective Registry

D. Smith, M. Jaros, Z. Molnár, 2021, Frontiers in Medicine.

Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation

Deepak L. Bhatt, U. Marathi, D. Angiolillo, 2020, Journal of Thrombosis and Thrombolysis.

Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials.

Deepak L. Bhatt, M. Price, H. White, 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Autonomic Neuropathy and Heart Disease

R. Nesto, E. Deliargyris, 1998 .

Association between periodontal disease and vulnerable plaque morphology in patients undergoing carotid endarterectomy

G. Kourlaba, C. Liapis, N. Liasis, 2020, International journal of cardiology. Heart & vasculature.

Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial

C. Hengstenberg, G. Dangas, S. Windecker, 2021, Clinical Research in Cardiology.

BIVALIRUDIN VERSUS HEPARIN WITH OR WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN STEMI PATIENTS UNDERGOING PRIMARY PCI: A POOLED ANALYSIS OF PATIENT-LEVEL DATA FROM THE HORIZONS-AMI AND EUROMAX TRIALS

B. Gersh, S. Pocock, G. Stone, 2014 .

REDUCED DEATH, MYOCARDIAL INFARCTION, AND EARLY STENT THROMBOSIS WITH CANGRELOR VERSUS CLOPIDOGREL ON A BACKGROUND OF BIVALIRUDIN: INSIGHTS FROM CHAMPION PHOENIX

Deepak L. Bhatt, M. Price, H. White, 2014 .

Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database

G. Stone, A. Kirtane, C. Meduri, 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Abstract 15919: Impact of Bivalirudin Therapy on Mortality in Patients With High Risk Features Undergoing PCI: A Patient-Level Pooled Analysis From the REPLACE-2, ACUITY and HORIZONS-AMI Trials

B. Gersh, G. Stone, G. Dangas, 2011 .

THE EFFICACY, SAFETY, AND NET CLINICAL BENEFIT OF CANGRELOR IN WOMEN UNDERGOING ELECTIVE OR URGENT PCI: INSIGHTS FROM THE CHAMPION-PHOENIX TRIAL

Deepak L. Bhatt, M. Price, H. White, 2015 .

CANGRELOR IN ELDERLY PATIENTS UNDERGOING PCI: FINDINGS FROM CHAMPION-PHOENIX

Deepak L. Bhatt, M. Price, H. White, 2015 .

Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding.

Deepak L. Bhatt, D. Cao, M. Chiarito, 2023, European heart journal.

Cost-Effectiveness and Budget Impact of a Novel Antithrombotic Drug Removal System to Reduce Bleeding Risk in Patients on Preoperative Ticagrelor Undergoing Cardiac Surgery

W. Padula, E. Deliargyris, F. Chingcuanco, 2023, American Journal of Cardiovascular Drugs.

Direct thrombin inhibitors in the treatment of immune-mediated heparin-induced thrombocytopenia.

D. Sane, E. Deliargyris, Jason T. Call, 2004, Seminars in thrombosis and hemostasis.

INCIDENCE OF ACUTE KIDNEY INJURY WITH BIVALIRUDIN OR UNFRACTIONATED HEPARIN FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT: RESULTS FROM THE BRAVO-3 RANDOMIZED TRIAL

C. Hengstenberg, P. Boekstegers, G. Dangas, 2017 .

Bivalirudin Is Associated With Improved In-Hospital Outcomes Compared With Heparin in Percutaneous Vascular Interventions: Observational, Propensity-Matched Analysis From the Premier Hospital Database

G. Dangas, H. Aronow, J. Prats, 2016 .

Intraoperative ticagrelor removal via hemoadsorption during on-pump coronary artery bypass grafting

R. Storey, M. Schmoeckel, D. Wendt, 2023, JTCVS open.

D. Dudek, K. Huber, P. Steg, 2013, American Heart Journal.

Trends in P2Y12 Inhibitor Use in Patients Referred for Invasive Evaluation of Coronary Artery Disease in Contemporary US Practice.

J. Prats, E. Deliargyris, S. Plent, 2016, The American journal of cardiology.

Influence of Lipid Excipients on Platelet Function and the Pharmacodynamic Effects of Aspirin

Heidi S. Taatjes‐Sommer, David J. Schneider, J. Prats, 2021, Journal of cardiovascular pharmacology.

Bivalirudin infusion to reduce ventricular infarction: the open-label, randomised Bivalirudin Infusion for Ventricular InfArction Limitation (BIVAL) study.

J. Garot, R. V. van Geuns, G. Sideris, 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

History Repeats Itself

E. Deliargyris, G. J. Dehmer, 2001 .

Cerebral Embolism During Transcatheter Aortic Valve Replacement The BRAVO-3 MRI Study

G. Dangas, E. Belle, O. Husser, 2022 .

Intraoperative haemoadsorption for antithrombotic drug removal during cardiac surgery: initial report of the international safe and timely antithrombotic removal (STAR) registry

E. Deliargyris, S. Geidel, K. Vitanova, 2024, Journal of thrombosis and thrombolysis.

Comparison of Bivalirudin Versus Heparin(s) During Percutaneous Coronary Interventions in Patients Receiving Prasugrel: A Propensity‐Matched Study

M. Valgimigli, A. Gershlick, F. Verheugt, 2014, Clinical cardiology.

D. Dudek, P. Steg, J. T. ten Berg, 2018, European heart journal. Acute cardiovascular care.

Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials

G. Stone, R. Mehran, P. Steg, 2017, European heart journal. Acute cardiovascular care.

The role of hemoadsorption in cardiac surgery – a systematic review

E. Deliargyris, S. Geidel, U. Livi, 2024, BMC cardiovascular disorders.